Fabrication, characterization and in vitro evaluation of PCL/PVA nanofibers loaded with docetaxel in breast cancer cells
Source abstract
Abstract
Breast cancer ranks as the second highest cause of mortality among women, and docetaxel (DTX) is a potent anticancer agent whose therapeutic effects can be optimized using nanofibers (NFs)-based drug delivery systems (DDSs). In this study, DTX-loaded NFs were fabricated using polycaprolactone (PCL) and polyvinyl alcohol (PVA) via electrospinning. Scanning electron microscopy (SEM) revealed smooth, bead-free morphology with random fiber orientation. Fourier-transform infrared spectroscopy (FTIR) confirmed successful DTX loading. In vitro drug release assays revealed an initial burst release of approximately 72% within the first 24 h, followed by sustained release over 4 days, resulting in a total of 90% drug release over 7 days. Cytotoxicity studies showed DTX-NFs induced a significant reduction in MCF-7 cell viability, with a 60% decrease in cell viability compared to the control group and a 40% increase compared to free DTX at the same concentration after 24 h. DTX-NFs reduced cell migration by 45% and colony formation decreased by 50% compared to the free DTX treatment. In conclusion, DTX-loaded PCL/PVA NFs demonstrated promising anticancer efficacy, sustained drug release and reduced migration and colony formation in MCF-7 cells, making them a potential strategy for postoperative local chemotherapy and prevention of breast cancer recurrence.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Sciences
Molecular and Medicine Research Center, Arak University of Medical Sciences
References (46)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1097/MD.000000000003690510.1097/MD.0000000000036905 ↗
3. 10.1016/j.jtemb.2024.12752610.1016/j.jtemb.2024.127526 ↗
4. 10.1016/j.msec.2021.11201910.1016/j.msec.2021.112019 ↗
5. 10.1016/j.ijbiomac.2024.13605810.1016/j.ijbiomac.2024.136058 ↗
6. 10.1016/j.drudis.2023.10384910.1016/j.drudis.2023.103849 ↗
7. 10.1016/j.cej.2024.15125310.1016/j.cej.2024.151253 ↗
8. Berko YA, Funmilola AF, Akala EO. Fabrication of paclitaxel and 17AAG-loaded poly-epsilon-caprolactone nanoparticles for breast cancer treatment. J Pharm Drug Deliv Res. 2021;10(1):196.
9. 10.1002/marc.20240090310.1002/marc.202400903 ↗
10. 10.2147/IJN.S44369210.2147/IJN.S443692 ↗
11. 10.1016/j.jddst.2022.10410410.1016/j.jddst.2022.104104 ↗
12. 10.1016/j.ijbiomac.2025.13966310.1016/j.ijbiomac.2025.139663 ↗
13. 10.23917/pharmacon.v21i2.698610.23917/pharmacon.v21i2.6986 ↗
14. 10.3390/polym1604050410.3390/polym16040504 ↗
15. 10.1002/jcb.2885210.1002/jcb.28852 ↗
16. 10.1016/j.scitotenv.2020.14167310.1016/j.scitotenv.2020.141673 ↗
17. 10.1515/ijmr-2023-012510.1515/ijmr-2023-0125 ↗
18. 10.3390/nano1415130510.3390/nano14151305 ↗
19. 10.1016/j.jddst.2024.10598110.1016/j.jddst.2024.105981 ↗
20. 10.1016/j.pmatsci.2024.10137610.1016/j.pmatsci.2024.101376 ↗
21. 10.1016/j.ijbiomac.2024.13398210.1016/j.ijbiomac.2024.133982 ↗
22. 10.2174/011570180835726725010205481010.2174/0115701808357267250102054810 ↗
23. 10.1007/s12668-024-01640-510.1007/s12668-024-01640-5 ↗
24. 10.4155/tde-2023-002010.4155/tde-2023-0020 ↗
25. 10.1186/s12967-024-05347-910.1186/s12967-024-05347-9 ↗
26. 10.3390/polym1506135510.3390/polym15061355 ↗
27. 10.1016/j.biopha.2022.11295110.1016/j.biopha.2022.112951 ↗
28. 10.1016/j.biomaterials.2014.04.09910.1016/j.biomaterials.2014.04.099 ↗
29. 10.1088/1758-5082/5/3/03500610.1088/1758-5082/5/3/035006 ↗
30. 10.22270/jddt.v7i6.153010.22270/jddt.v7i6.1530 ↗
31. 10.1016/j.ceramint.2014.01.05810.1016/j.ceramint.2014.01.058 ↗
32. 10.1007/s40204-017-0062-110.1007/s40204-017-0062-1 ↗
33. 10.1295/polymj.36.69510.1295/polymj.36.695 ↗
34. 10.1134/S107042722103017410.1134/S1070427221030174 ↗
35. 10.1111/aor.1371310.1111/aor.13713 ↗
36. 10.1016/j.ctrv.2007.01.00710.1016/j.ctrv.2007.01.007 ↗
37. 10.2174/156652402366623072414135310.2174/1566524023666230724141353 ↗
38. 10.1080/03639045.2022.216155910.1080/03639045.2022.2161559 ↗
39. 10.2147/BCTT.S43252610.2147/BCTT.S432526 ↗
40. 10.1007/s12031-023-02174-310.1007/s12031-023-02174-3 ↗
41. 10.1016/s0939-6411(03)00095-x10.1016/s0939-6411(03)00095-x ↗
42. 10.1016/j.athoracsur.2010.12.04010.1016/j.athoracsur.2010.12.040 ↗
43. 10.1039/c2nr30731f10.1039/c2nr30731f ↗
44. 10.1245/s10434-009-0856-z10.1245/s10434-009-0856-z ↗
45. 10.1016/j.lfs.2024.12263510.1016/j.lfs.2024.122635 ↗
46. 10.1016/j.drup.2011.01.00310.1016/j.drup.2011.01.003 ↗